Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 9, 2011, Pages 1007-1013

  McAlister, Finlay A ^a   Wilkins, Kathryn ^b   Joffres, Michel ^c   Leenen, Frans H H ^d   Fodor, George ^d   Gee, Marianne ^e   Tremblay, Mark S ^f   Walker, Robin ^g   Johansen, Helen ^b   Campbell, Norm ^g  

^a UNIVERSITY OF ALBERTA   (Canada)

^b STATISTICS CANADA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^f CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^g LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; COMORBIDITY; DISEASE CONTROL; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; POPULATION RESEARCH; PREVALENCE; SYSTOLIC BLOOD PRESSURE;

EID: 79958759601     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.101767     Document Type: Article

References (34)

1. Lawes CMM, Vander Hoorn S, Law MR, et al. Blood pressure and the global burden of disease 2000. Part II: Estimates of attributable burden. J Hypertens 2006;24:423-30.
2. Lewington S, Clarke R, Qizilbash N, et al; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
3. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
4. McAlister FA. The treatment of hypertension in Canada: Are we making progress? CMAJ 1999;161:713-4.
5. Campbell NRC, Tu K, Brant R, et al. The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends. Hypertension 2006;47:22-8. (Pubitemid 43177810)
6. Campbell NRC, Brant R, Johansen H, et al. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension 2009;53:128-34.
7. Leenen FH, Dumais J, McInnis NH, et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008; 178:1441-9. (Pubitemid 351775721)
8. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004;22:11-19. (Pubitemid 38293521)
9. Pereira M, Lunet N, Azevedo A, et al. Differences in prevalence, awareness, treatment, and control of hypertension between developing and developed countries. J Hypertens 2009;27:963-75.
10. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-50.
11. Joffres MR, Ghadirian P, Fodor JG, et al. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10:1097-102. (Pubitemid 27486342)
12. Wilkins K, Campbell NRC, Joffres MR, et al. Blood pressure in Canadian adults. Health Rep 2010;21:37-46.
13. Myers MG, McInnis NH, Fodor GJ, et al. Comparison between an automated and manual sphygmomanometer in a population survey. Am J Hypertens 2008;21:280-3. (Pubitemid 351323269)
14. Rust KF, Rao JNK. Variance estimation for complex surveys using replication techniques. Stat Methods Med Res 1996;5:283-310. (Pubitemid 126559356)
15. Tu K, Campbell NRC, Durong-Hua M, et al. Hypertension management in the elderly has improved: Ontario prescribing trends, 1994 to 2002. Hypertension 2005;45:1113-8.
16. Muntner P, Krousel-Wood M, Hyre A, et al. Antihypertensive prescription for newly treated patients before and after the main antihypertensive and lipid-lowering treatment to prevent heart attack trial results and seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure guidelines. Hypertension 2009;53:617-23.
17. McAlister FA, Feldman RD, Wyard K, et al. Campbell N for the CHEP Outcomes Research Task Force. The impact of the Canadian Hypertension Education Program in its first decade. Eur Heart J 2009;30:1434-9.
18. Tu K, Chen Z, Lipscombe LL. Prevalence and incidence of hypertension from 1995 to 2005: a population-based study. CMAJ 2008;178:1429-35.
19. Joffres MR, Campbell NRC, Manns B, et al. Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health costs in Canada. Can J Cardiol 2007;23:437-43. (Pubitemid 46977999)
20. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians. Arch Intern Med 2000;160:2281-6.
21. Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162:413-20. (Pubitemid 34150642)
22. McAlister FA, Laupacis A, Teo KK, et al. A survey of clinician attitudes and management practices in hypertension. J Hum Hypertens 1997;11:413-9. (Pubitemid 27389170)
23. Wong ND, Thakral G, Franklin SS, et al. Preventing heart disease by controlling hypertension: impact of hypertensive subtype, stage, age, and sex. Am Heart J 2003;145:888-95. (Pubitemid 36570961)
24. Petrella RJ, Merikle E. A retrospective analysis of the prevalence and treatment of hypertension and dyslipidemia in southwestern Ontario, Canada. Clin Ther 2008;30:1145-54. (Pubitemid 351978118)
25. Thoenes M, Neuberger HR, Volpe M, et al. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 2010;24:336-44.
26. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007;167:141-7. (Pubitemid 46151611)
27. Belletti DA, Zacker C, Wogen J. Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States. Cardiovasc Diabetol 2010;9:7.
28. Emberson J, Whincup P, Morris R, et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004;25:484-91. (Pubitemid 38524273)
29. Birkett NJ. The effect of alternative criteria for hypertension on estimates of prevalence and control. J Hypertens 1997;15:237-44. (Pubitemid 27129112)
30. Leenen FHH, Schiffrin EL. Control rates of hypertension in North America. Hypertension 2010;56:571-2.
31. Cushman WC, Evans GW, Byington RP, et al; The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
32. McAlister FA, Kelly N, Chen G, et al.; the Canadian Hypertension Education Program Outcomes Research Task Force and Blood Pressure Canada. Canadian Hypertension Education Program Evaluation Project: a comparison of changes in Canadian hypertension treatment, hypertension diagnosis, and cardiovascular disease rates to other national hypertension management programs. A report for the Public Health Agency of Canada, Management Division, Centre for Disease Prevention and Control. 2009 Mar. 31.
33. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011;377:568-77.
34. Majumdar SR, McAlister FA, Furberg CD. From publication to practice in chronic cardiovascular disease - the long and winding road. J Am Coll Cardiol 2004;43:1738-42. (Pubitemid 38622507)